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268 The Journal of Thoracic and CardioObjectives: Overexpression of angiopoietin 1 in the lung has been associated with
human pulmonary hypertension. We hypothesized that inhibiting angiopoietin 1
signaling in the lung by administration of a receptor antagonist would block the
development of pulmonary hypertensive vasculopathy in rodent models.
Methods: We injected 2 and 4  1010 genomic particles of adeno-associated virus
containing an extracellular fragment of the TIE2 receptor (AAV-sTIE2) into the pul-
monary artery of 60 rats by using adeno-associated virus–lacZ and carrier-injected rats
as control animals. Pulmonary hypertension was then induced by each of the following
methods: (1) monocrotaline (group 1); (2) angiopoietin 1 expression in pulmonary
vascular smooth muscle by adeno-associated virus gene transfer (group 2); or (3)
oxygen deprivation (group 3). Animals were sacrificed at serial time points. At each
time point, pulmonary artery pressures were measured, and pulmonary angiography was
performed. Lungs were harvested for pathologic-molecular analysis.
Results: Each rodent pulmonary hypertension model demonstrated a significant in-
crease in pulmonary artery pressures compared with that seen in control animals (P 
.01). Administration of AAV-sTIE2 prevented pulmonary hypertension in the mono-
crotaline and angiopoietin 1 groups (from 44.6  2.1 to 18.8  1.9 mm Hg in the
monocrotaline group and from 31.2  3.7 to 18.2  1.8 mm Hg in the angiopoietin 1
group, P  .001) but did not affect pulmonary hypertension in the hypoxia group.
Pathologic analysis of group 1 and 2 lungs treated with AAV-sTIE2 demonstrated
absence of smooth muscle cell proliferation within arterioles. Pulmonary angiography
confirmed a lack of small pulmonary vessel occlusion in group 1 and 2 animals treated
with AAV-sTIE2.
Conclusions: Molecular blocking of the interaction between angiopoietin 1 and its
endothelial receptor, TIE2, in the lung prevents pulmonary hypertension in 2 animal
models of the disease. These experiments suggest a new strategy for understanding
pulmonary hypertension based on the molecular biology of the pulmonary vascular wall.
Pulmonary hypertension (PH) is a disease characterized by prolifera-tion of vascular smooth muscle cells and asymmetric neointimalendothelial hyperplasia around small pulmonary arteries and arte-rioles.1 Muscle cell proliferation around pulmonary vessels occurs inall forms of PH, including idiopathic disease, as well as that inducedby drugs, thromboembolism, or intracardiac shunt.2-4 Several lines of
evidence have suggested that angiopoietin 1 (Ang-1), a secreted peptide ligand,
regulates physiologic vascular smooth muscle proliferation in utero and contributes
to pathologic smooth muscle cell proliferation around vessels in PH. First, mice
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ing from a lack of muscular investment around blood ves-
sels, particularly in the lung.5 Second, targeted overexpres-
sion of Ang-1 in the lungs of rodents causes clinical and
pathologic PH characterized by severe muscularization of
Figure 1. TIE2 receptor with a unique extracellular ligand– bind-
ing domain comprised of immunoglobulin (IG) domains, epithelial
growth factor (EGF) repeats, and fibronectin-like 3 (FN3) repeats
is a transmembrane protein with intracellular tyrosine kinase
domain. Soluble TIE2 (sTIE2), a competitive inhibitor of TIE2
activation, is composed of the extracellular ligand– binding do-
main only.
Figure 2. Flow sheet of treatment strategies. AAV, Adeno-asso-
ciated virus; sTIE2, soluble TIE2; FIO2, fraction of inspired oxygen;
SC, subcutaneous.pulmonary arterioles.6,7 Third, Ang-1 is constitutively ex-
The Journal of Thoracipressed in the lungs of patients with different causes of PH
and is absent in normal adult lung tissue.8 Taken together,
these results suggest a causal role for Ang-1 in the vascu-
lopathy of PH.
Ang-1 exerts its effect through the endothelial-specific
tyrosine kinase receptor TIE2.9 In lung vascular develop-
ment, both Ang-1 and TIE2 are expressed in growing blood
vessels: Ang-1 is made and secreted by vascular smooth
muscle cells and precursor pericytes, whereas TIE2 is a
transmembrane receptor expressed on the surface of endo-
thelial cells.10 Once development is complete, Ang-1 ex-
pression is almost undetectable, whereas TIE2 expression
remains constitutive. It is unknown what signals reactivate
constitutive Ang-1 gene expression in the pulmonary hy-
Figure 3. A, Photomicrographs of hematoxylin and eosin–stained
rat pulmonary arterioles from 3 animal models of PH and respec-
tive control animals. The top panel compares monocrotaline-
induced pathology to control injection of PBS. The middle panel
compares hypoxia-induced pathology with normoxic lung. The
bottom panel demonstrates AAV–Ang-1–induced pathology com-
pared with that seen in lungs injected with AAV-lacZ or PBS-
carrier. The scale bar represents 40 m. B, Northern blot dem-
onstrating constitutive Ang-1 expression in the lungs of animals
with 3 types of PH. Transcript lengths are shown on the right. SC,
Subcutaneous injection; FIO2, fraction of inspired oxygen.pertensive lung.
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naling pathway in the lung vasculature would prevent the
development of PH. To this end, we examined whether an
extracellular fragment of the TIE2 receptor (sTIE2, a pep-
tide retaining the binding site for Ang-1) would serve as a
competitive inhibitor of this receptor-ligand interaction and
prevent development of PH when expressed in the pulmo-
nary vascular wall. The effect of sTIE2 gene administration
using an adeno-associated viral vector (AAV) to the lung
was tested in 3 rodent models of PH.
Materials and Methods
Vector Construction and Gene Transfer
A cDNA containing nucleotides 1 to 2236 of the murine TIE2
receptor was generated by standard cloning techniques and named
soluble TIE2-cDNA (sTIE2-cDNA). The sTIE2-cDNA codes for
the extracellular domain of TIE2 (amino acids 1-744) and encom-
passes 3 fibronectin type III domains adjacent to 3 epidermal
growth factor-like repeats between 2 immunoglobulin-like loops
(Figure 1).11 The sTIE2 peptide has been shown to block Ang-1
binding to TIE2 in vitro.12 The final cDNA was verified by means
of sequencing with an ABI-PRISM 3100 Genetic Analyzer (Ap-
plied Biosystems, Foster City, Calif) and inserted into the pAAV-
shuttle plasmid to create pAAV-sTIE2. Large-scale recombinant
serotype 2 AAV containing sTIE2, murine Ang-1, or lacZ was
produced, purified, and titered as previously reported.13 The con-
centration of the vectors was determined by means of real-time
polymerase chain reaction (PCR) with the SYBR Green detection
kit (Applied Biosystems). All viral preparations had at least 1 
TABLE 1. Pressure transduction in 3 models of pulmonary
PA pressure (mm
Systolic
Group 1
Monocrotaline (SC) 45.8 3.7*
PBS (SC) 16.2 1.5
Group 2
AAV-Ang-1
21010 GP 33.6 2.4†
41010 GP 31.8 2.6†
AAV-sTIE2
21010 GP 15.8 1.3
41010 GP 15.8 1.6
AAV-lacZ
21010 GP 16.0 1.6
41010 GP 16.2 2.4
PBS-carrier 16.4 1.1
Group 3
Hypoxia 42.8 3.2*
Normoxia 15.2 1.5
Values are reported as means  SD. PA pressure, Pulmonary arterial pres
injected per rat; AAV, adeno-associated virus; Ang-1, angiopoietin 1; sTIE
*P  .01 compared with control group: PBS (SC) group.
†P  .001 compared with 3 control groups: AAV-sTIE2, AAV-lacZ, and PB1011 genomic particles (GP)/mL. Vectors were retested for trans-
270 The Journal of Thoracic and Cardiovascular Surgery ● Febrgene expression by infecting 293T cells. Twelve-week-old Fischer
rats (Harlan, San Diego, Calif) were anesthetized with intraperi-
toneal injection of ketamine (50 mg/kg)–xylazine (10 mg/kg).
Animals were intubated and ventilated with a Harvard rodent
ventilator Model 683 (Harvard Apparatus, Holliston, Mass). The
heart was exposed through a left thoracotomy at the fourth inter-
costal space. Injections were made into the main pulmonary artery
while occluding the pulmonary veins for 5 seconds. All viral
injections consisted of 200 L of phosphate-buffered saline
(PBS)–1 mmol/L MgCl2 containing the number of viral GP indi-
cated below. Animal experiments were approved by the University
of California, San Diego Animal Care Committee and were in
compliance with the “Guide for Care and Use of Laboratory
Animals” (www.nap.edu/catalog/5140.html, revised 1996).
Animal Models
Separate treatment groups were used to examine the effects of
sTIE2 in 3 models of PH (Figure 2). Group 1 animals received
monocrotaline, a pyrrolizidine alkaloid (Sigma Aldrich, St. Louis,
Mo), that is known to induce PH 2 to 3 weeks after subcutaneous
injection.14 Group 2 animals had pulmonary arterial injections of
AAV-Ang-1, which is known to induce PH 4 weeks after gene
transduction.6 Group 3 animals were placed in a hypoxia chamber
and allowed to breathe 10% oxygen for 3 weeks to induce PH.15
Experiments for each group were performed in duplicate, with 5
animals per treatment within each subgroup. Groups 1 and 3
received injections of AAV-sTIE2 (2  1010 and 4  1010 GP per
rat), AAV-lacZ (2  1010 and 4  1010 GP per rat), or PBS–1
mmol/L MgCl2 (PBS-carrier) at week 0. At week 4, group 1
animals received subcutaneous injections of either monocrotaline
ertension
Aortic pressure (mm Hg)
iastolic Systolic Diastolic
8 3.4* 102.4 5.7 76.4  2.7
8 1.3 109.2 3.4 75.8  5.1
2 2.6† 106.8 10.5 75.2  5.5
6 2.3† 106.4 4.0 74.8  4.7
0 1.6 104.8 4.6 75.2  3.8
6 1.1 107.2 4.9 72.2  4.0
0 1.2 107.6 3.4 76.8  4.2
2 1.9 108.4 3.9 74.4  4.8
8 0.8 101.2 3.1 73.6  4.1
4 3.3* 102.2 4.3 71.8  5.8
0 1.0 106.8 7.0 74.4  2.7
SC, subcutaneous; PBS, phosphate-buffered saline; GP, genomic particles
uble TIE2.
rrier groups.hyp
Hg)
D
22.
7.
17.
16.
8.
7.
7.
8.
7.
21.
6.
sure;
2, solat 60 mg/kg or diluent alone, whereas group 3 animals were
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oxygen) in a 14-cubic-feet hypobaric chamber or ambient air.
Group 2 received control injections of either AAV-Ang-1 (2 
1010 and 4  1010 GP per rat), AAV-sTIE2 (2  1010 and 4 
1010 GP per rat), AAV-lacZ (2  1010 and 4  1010 GP per rat),
or PBS-carrier, as well as combination injections of AAV-Ang-1
(2  1010 GP per rat) plus AAV-sTIE2 (in doses of 2 or 4  1010
GP per rat), AAV-Ang-1 (2 1010 GP per rat) plus AAV-lacZ (in
doses of 2 or 4  1010 GP per rat), or AAV-Ang-1 (2  1010 GP
per rat) plus PBS-carrier made at week 0. No treatment was made
at week 4. All animals were sacrificed at week 7.
Hemodynamic Measurements and Pulmonary
Angiography
Prior to sacrificing animals, pulmonary artery pressures were trans-
duced with a 22-gauge angiocatheter directed into the main pul-
Figure 4. A, Lung specimens 4 and 7 weeks after injection with
AAV-sTIE2, AAV-lacZ, or PBS carrier tested for sTIE2 expression
by means of RT-PCR. The transgene sTIE2 was constitutively
expressed in the lungs of animals injected with AAV-sTIE2 only.
B, Pathologic changes in lung specimens (hematoxylin and eosin
stain). Injection of AAV-sTIE2 prevented pulmonary arteriolar
smooth muscle hyperplasia in monocrotaline- and Ang-1–induced
models of PH but had no effect on hypoxia-induced PH. The scale
bar represents 50 m.monary artery after insertion into the right ventricular outflow
The Journal of Thoracitract, while systemic pressures were measured by means of direct
aortic transduction (pressure transducer from SpaceLabs, Inc, Is-
saquah, Wash). For angiography, animals were sacrificed by ex-
sanguination through the abdominal aorta. The pulmonary artery
was flushed with 4 mL of PBS. Lungs were perfused through the
Figure 5. Pulmonary angiograms using the Microfil cast tech-
nique of rodent lungs with PH induced by either monocrotaline
(A), constitutive Ang-1 expression (B), or hypoxia (C) treated or
untreated with AAV-sTIE2. Note the absence of peripheral vessel
staining in the lungs of all 3 models of PH, which is indicative of
small-vessel occlusion and normal pulmonary vascular tree in
lungs of animals treated with sTIE2. The scale bar represents 25
mm.pulmonary artery with 0.25 mL/min Microfil (Flow Tech, Carver,
c and Cardiovascular Surgery ● Volume 129, Number 2 271
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Apparatus). Lungs were incubated at 4°C for 12 hours, bathed in
serial concentrations of ethanol, placed in methyl salicylate, and
photographed with a digital camera after magnification (Leica S6D
dissecting microscope, Heerbrugg, Switzerland).
Tissue Processing and Histology
Lungs were fixed in 4% paraformaldehyde, embedded in paraffin,
and sectioned at 5 m thickness. Sections were stained with
hematoxylin and eosin and examined by means of digital photomi-
croscopy at various magnifications to determine the severity of PH.
A pathologist blinded to the study reviewed 10 sections per lung
and determined, for vessels 50 to 500 m in diameter, the per-
centage with medial hyperplasia and the percentage occluded, as
well as the number of myocytes per vessel wall for vessels less
than 125 m in diameter.
RNA Methods
Reverse transcriptase PCR (RT-PCR) and Northern blotting were
performed as previously described.8 For RT-PCR, primer pairs
TABLE 2. Morphometric analysis of vascular lesions and
Treatment
Disease
induction
Vessels
occluded*
(%)
Vessels with
media
hyperplasia* (%)
Group 1
PBS Monocrotaline 36.6 2.6 82.2 5.8
AAV-sTIE2
21010 GP Monocrotaline 3.2 2.8‡ 10.6 2.9‡
41010 GP Monocrotaline 2.5 1.9‡ 9.0 1.8‡
AAV-lacZ
21010 GP Monocrotaline 34.2 6.6 84.5 4.1
41010 GP Monocrotaline 35.9 4.6 83.5 7.6
Group 2
PBS AAV-Ang-1 25.5 6.1 75.5 6.6
AAV-sTIE2
21010 GP AAV-Ang-1 2.9 1.9§ 8.3 2.4§
41010 GP AAV-Ang-1 2.2 1.4§ 6.0 3.0§
AAV-lacZ
21010 GP AAV-Ang-1 25.0 5.2 74.9 4.6
41010 GP AAV-Ang-1 25.3 9.6 76.6 4.7
Group 3
PBS Hypoxia 6.9 2.5 75.6 4.3
AAV-sTIE2
21010 GP Hypoxia 5.0 2.6 58.8 8.1
41010 GP Hypoxia 4.8 1.9 55.6 6.6
AAV-lacZ
21010 GP Hypoxia 6.3 2.0 74.8 5.0
41010 GP Hypoxia 6.5 3.4 75.6 4.9
Values are reported as means  SD. PA pressure, Pulmonary arterial p
soluble TIE2; GP, genomic particles injected per rat.
*Vessels 50-500 m.
†Vessels 125 m.
‡P  .001 compared with PBS and AAV-lacZ injection in group 1.
§P  .001 compared with PBS and AAV-lacZ injection in group 2.used were as follows: viral-specific sTIE2, 5=-CTGCTTGGAC-
272 The Journal of Thoracic and Cardiovascular Surgery ● FebrCCTTAGTGACATT-3= (derived from a murine sequence) and
5=-GTATCGATAAGCTTGATATCTCTTC-3= (derived from
polyadenylation sequence in our viral construct); glyceraldehyde-
3-phosphate dehydrogenase (GAPDH),9 5=-CATCATCTCTGC-
CCCCTCTG-3= and 5=-CCTGCTTCACCACCTTCTTG-3=. For
Northern blots, membranes were incubated with phosphorous 32–
labeled probes generated by RT-PCR from total rat RNA with the
following primer pairs: Ang-1, 5=-TGGAGGGAAAACACAAG-
GAAGAGC-3= and 5=-TAAGGGCGCATTTGCACATACAGT-
3= (derived from mouse/rat sequence); GAPDH, same as above.
Primer pairs listed were derived from the National Institutes of
Health rat-mouse gene bank at www.NCBI.NLM.NIH.gov by us-
ing DNAstar primer select software (DNASTAR, Inc, Madison,
Wis). sTIE2 and Ang-1 reaction products were sequenced (ABI-
PRISM 3100 Genetic Analyzer) to verify amplification of the
expected sequences.
Statistical Analysis
Means  SD for direct measurements and means  SEM for
treatment differences are reported. Wilcoxon Mann-Whitney exact
sure measurement
ean no. of
yocytes
ssel wall†
PA pressure (mm Hg) Aortic pressure (mm Hg)
Systolic Diastolic Systolic Diastolic
.3  7.5 44.6  2.1 24.8 4.1 105.4  3.7 72.6  4.8
.0  4.7‡ 18.8 1.9‡ 9.2 1.5‡ 106.2 6.6 76.6  8.0
.8 5.2‡ 17.2 2.2‡ 8.2 0.8‡ 107.2 2.6 74.2  3.7
.6  9.3 46.8  3.4 26.2 3.1 104.6  4.5 74.2  5.2
.6  9.0 45.4  2.1 23.6 2.9 105.8  5.3 72.8  7.6
.4  6.4 31.2  3.7 15.2 2.7 108.6  3.7 75.4  4.7
.2 2.9§ 18.2 1.8§ 7.8 0.8§ 103.4 10.3 73.4  14.0
.2 6.0§ 15.6 1.5§ 7.6 1.1§ 107.8 4.3 77.8  4.7
.4  8.2 34.6  2.3 15.6 2.4 108.0  3.7 72.2  3.2
.6  6.9 31.8  2.9 16.8 1.6 105.6  4.6 70.4  4.5
.8  6.8 40.4  3.5 20.8 2.9 96.4 2.7 70.2  2.8
.8  4.5 39.4  2.1 19.2 2.5 97.6 4.3 70.8  9.6
.2  4.8 39.8  6.5 19.2 4.2 97.0 5.1 72.4  5.3
.6  5.9 43.6  4.0 21.8 1.8 100.4  2.8 71.8  3.1
.8  4.7 42.6  3.1 22.0 3.4 98.8 3.6 70.4  3.4
re; PBS, phosphate-buffered saline; AAV, adeno-associated virus; sTIE2,pres
M
m
ve
34
12
11
33
31
30
12
11
29
31
20
18
17
19
19
ressutests performed with StatXact with Cytel Studio software (Version
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test hypotheses of differences. Unadjusted observed significance
levels (P values) are reported.
Results
Animal Models of PH and Ang-1 Expression
Pulmonary hypertensive pathology was induced by one of 3
different methods: monocrotaline administration (group 1),
injection of AAV–Ang-1 into the main pulmonary artery
(group 2), or hypoxic conditioning (group 3). To confirm that
pulmonary hypertensive pathology developed in each animal
model, rats in each group (and their respective control animals)
were sacrificed, and their lungs were examined for pulmonary
hypertensive changes (Figure 3, A). All 3 methods induced
pulmonary hypertensive vascular changes and measurable PH
(Table 1). Lungs from animals in all groups demonstrated
severe muscular hyperplasia in the medial layer of the pulmo-
nary arteries and arterioles measuring less than 500 m in
diameter. Northern analysis of tissue after monocrotaline in-
jection, AAV–Ang-1 injection, or oxygen deprivation con-
firmed high steady-state levels of Ang-1 transcripts in pulmo-
nary hypertensive lungs compared with that seen in control
lungs (Figure 3, B). All 3 models of rodent PH were charac-
terized by constitutive expression of Ang-1 mRNA in the lung.
Effect of AAV-sTIE2 on Rodent Pulmonary
Hypertensive Pathology
An experimental flow sheet is described in Figure 2. To
determine whether constitutive expression of sTIE2 in the
lung could block the development of PH, we injected AAV-
sTIE2 in 2 doses (2  1010 GP per rat, 30 total animals; 4
 1010 GP per rat, 30 total animals), AAV-lacZ (2  1010
GP per rat, 30 total animals; 4  1010 GP per rat, 30 total
animals), or an equal volume of PBS-carrier (200 L per
rat, 30 total animals) into the main pulmonary arteries of the
rats. RT-PCR analysis at 4 and 7 weeks after injection
confirmed that vector-specific sTIE2 transcripts were
present in lungs injected with AAV-sTIE2 but were not
detected in lungs injected with AAV-lacZ or PBS-carrier
(Figure 4, A). After induction of PH by monocrotaline
injection, oxygenation deprivation, or injection of AAV–
Ang-1, animals who had received pretreatment with AAV-
sTIE2, AAV-lacZ, or PBS-carrier were sacrificed, and their
lungs were examined for vascular pathology.
Delivery of AAV-sTIE2 to the lung protected against the
development of PH in monocrotaline-injected animals (Fig-
ure 4, B). Small-vessel medial hyperplasia was present in
less than 11% of blood vessels examined. In contrast, de-
livery of control virus, AAV-lacZ, had no effect on mono-
crotaline-induced PH, with greater than 80% of blood ves-
sels examined displaying medial hyperplasia and 34% of
pulmonary arterioles occluded from smooth muscle cell
proliferation (Table 2). The protective effect of sTIE2 oc-
curred with both doses of viral vector administered and
The Journal of Thoracioccurred irrespective of AAV-sTIE2 viral preparation. In a
similar way, AAV-sTIE2 protected rodent lungs against the
development of Ang-1–induced PH, blocking the develop-
ment of small-arteriole muscular hyperplasia (Figure 4, B).
Ang-1 animals constitutively expressing sTIE2 in the lung
had less than 9% of pulmonary arterioles (500 m) with
medial thickening, whereas Ang-1 animals constitutively
expressing lacZ in the lung had greater than 74% of pul-
monary arterioles affected (Table 2).
In contrast, administration of AAV-sTIE2 did not affect
the development of hypoxic PH. Severe pulmonary hyper-
tensive lung pathology was seen in animals injected with
either AAV-sTIE2 or the control AAV-lacZ vector, and
lung pathology in these 2 groups was indistinguishable.
Oxygen-deprived animals had medial hyperplasia in ap-
proximately 75% of pulmonary arterioles measuring less
than 500 m in diameter, and this process was not attenu-
ated by sTIE2.
sTIE2 Prevents PH in 2 Models of the Disease
For groups 1 and 2 (monocrotaline- and Ang-1–induced
PH), animals expressing sTIE2 demonstrated a significant
decrease in pulmonary systolic and diastolic pressures (Ta-
ble 2) compared with that seen in control animals, which
was reproducible over a 10-minute period before the ani-
mals were sacrificed (mean [SEM] decrease, 28.1 [1.1] and
16.2 [1.1] mm Hg for pulmonary artery systolic and dia-
stolic pressures, respectively, for group 1 animals treated
with AAV-sTIE2; 16.3 [1.1] and 8.5 [0.7] mm Hg for
pulmonary artery systolic and diastolic pressures, respec-
tively, for group 2 animals treated with AAV-sTIE2). This
represented a selective decrease in pulmonary artery pres-
sures because systemic arterial blood pressures were un-
changed compared with baseline measurements taken be-
fore gene transfer. Pulmonary artery pressures for animals
constitutively expressing sTIE2 in the monocrotaline and
Ang-1 groups were significantly decreased (all P  .001)
compared with pressures measured in control animals. For
group 3 (hypoxic PH), sTIE2 had little effect on pulmonary
artery pressures (mean [SEM] change of 3.5 [1.8] and 2.9
[1.3] mm Hg for pulmonary artery systolic and diastolic
pressures, respectively; P  .07). Animals in this group
manifest significant increases in pulmonary arterial systolic
and diastolic pressures compared with systemic pressure.
An in vivo polymer perfusion technique16 was used to
perform pulmonary arteriography. Group 1 and 2 animals
(monocrotaline- and Ang-1–induced PH) had pulmonary
angiograms demonstrating severe small-vessel pruning sim-
ilar to that seen in human PH (Figure 5, A and B). However,
animals in these groups treated with AAV-sTIE2 had nor-
mal pulmonary angiograms, suggesting that high levels of
sTIE2 in the lung blocked the development of disease in
these 2 animal models. In contrast, sTIE2 had little protec-
c and Cardiovascular Surgery ● Volume 129, Number 2 273
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small-vessel occlusion-stenosis. Animals in group 3 (hy-
poxic PH) had pulmonary angiograms displaying diffuse
small-vessel stenosis-occlusion, regardless of whether they
had been treated with AAV-sTIE2 (Figure 5, C).
Discussion
PH is a debilitating and lethal disease that is characterized
by small-vessel vasculopathy in the lung. The pathologic
hallmark of this disease is polyclonal smooth muscle cell
proliferation in the medial layer of small pulmonary arteries
and arterioles. The clinical manifestation of this vasculopa-
thy is markedly increased pulmonary artery pressure com-
pared with systemic arterial pressure. Although clinical
triggers for this disease are known (hypoxia, increased
pulmonary circulation, thromboembolism, and chemical
damage), the molecular mechanism responsible for the
common lung pathology seen with each of these inciting
factors is unknown. Current treatment modalities, such as
prostacyclin analogs, endothelin receptor antagonists, and
nitric oxide, have been shown to be effective in relieving the
pulmonary arteriolar vasoreactive component of this dis-
ease; however, none of these drugs is known to alleviate the
progressive muscularization of small pulmonary vessels that
ultimately leads to right heart failure and death.17,18
Our goal has been to block specific gene products that
control the development of vasculopathy in PH to effec-
tively treat or prevent this disease. As a result of the work
reported here, we have 4 major conclusions. First, 3 animal
models for PH are characterized by overexpression of the
same gene, Ang-1. Second, although they look similar at the
pathologic level, animal models for PH do not use the same
biochemical-molecular pathway to generate small-vessel
muscular hyperplasia. Third, constitutive levels of sTIE2,
an antagonist of Ang-1, block the development of PH in 2
animal models of this disease. Our studies suggest that
monocrotaline-induced PH works through an Ang-1–related
pathway. Fourth, sTIE2 is ineffective in preventing PH
induced by oxygen deprivation. The phenotypes observed
with gene transfer were not due to viral vector, vector
preparation, surgical delivery, or carrier solution used. The
AAV constructs used in these experiments did not stimulate
perivascular lymphocytic infiltration or inflammatory reac-
tion in lung tissue, as has been seen with gene delivery
systems to the lung.19 Our results suggest that a molecular
strategy that blocks the Ang-1–TIE2 signaling pathway is
an effective treatment for preventing rodent PH. From a
mechanistic point of view, we believe that blocking Ang-
1–induced activation of the TIE2 receptor is fundamental to
preventing paracrine cellular signaling that culminates in a
vascular smooth muscle cell proliferative response.
Recently, our group has shown a link between overex-
pression of Ang-1 in the lung and the development of PH.6,7
274 The Journal of Thoracic and Cardiovascular Surgery ● FebrIndeed, constitutive Ang-1 expression in the adult rodent
lung leads to an exaggerated and organ-specific vascular
smooth muscle proliferative response. Most forms of human
PH are also characterized by high levels of Ang-1 in vas-
cular endothelium.8 This gene expression pattern is not seen
in normotensive human lung tissue. We have found that
rodent monocrotaline-induced PH is caused by an Ang-1–
related pathway and can be effectively prevented by high
levels of Ang-1–specific antagonist in pulmonary endothe-
lium. In a similar way PH induced by constitutive Ang-1
expression (from viral gene delivery) can be effectively
prevented by administration of AAV-sTIE2. These findings
link monocrotaline and Ang-1–induced PH in the rodent as
having a similar biochemical backbone and response to
treatment.
We found that hypoxic PH is a different disease at the
molecular level from other forms of PH in that it showed
little response to treatment with sTIE2. Although Ang-1
levels were increased in lung tissue from animals with this
form of disease, we speculate that hypoxic PH does not
work solely through an Ang-1–TIE2 pathway. Rather, hy-
poxic PH may be caused by other parallel molecular path-
ways that circumvent the obligate need for endothelial TIE2
activation. The reversible nature of hypoxic PH also con-
trasts with most human forms of the disease, where smooth
muscle cell hyperplasia in pulmonary arterioles is perma-
nent.
Clues as to the pathogenesis of PH and treatment strat-
egies for this disease come from a growing body of litera-
ture about molecular cross-talk that occurs between vascular
endothelium and smooth muscle cells. This cell-to-cell
communication is regulated by paracrine signals between
muscle-secreted peptides and transmembrane tyrosine ki-
nase receptors on endothelial cells.20 It is widely believed
that endothelial cells, through secretion of factors, modula-
tion of cell-surface proteins, or both, regulate the prolifer-
ation of smooth muscle cells in their vicinity. Ang-1, the
muscle-secreted ligand most studied to date, is known to
bind the endothelial-restricted receptor TIE2, resulting in
tyrosine phosphorylation and activation of this receptor into
an active tyrosine kinase.21 Ang-1 signaling through TIE2 is
known to result in the following: (1) the release of the
paracrine smooth muscle cell growth factor 5-hydroxytryp-
tamine (serotonin) by vascular endothelial cells7; (2) the
transcriptional downregulation of the BMPR1a gene,8
whose sister receptor, BMPR2, is characterized by haploid
mutation in inherited forms of human PH22; and (3) the
upregulation of the apoptosis inhibitor survivin through the
serine threonine kinase pathway Akt, thereby protecting
endothelium from programmed cell death.23,24 Each of
these downstream intracellular pathways may contribute to
the pathogenesis of this disease. Efforts to block TIE2
intracellular endothelial signaling in PH at other more
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ment strategies for this disease.
Several limitations to this study deserve comment. First,
animal treatments were based on the transduction of a
specific gene product (a truncated extracellular fragment of
the TIE2 receptor sTIE2) for only 50 days after gene deliv-
ery in a vector system (AAV) that does not achieve high
levels of transgene expression until approximately 1 month
after gene delivery.12 This is an inherent limitation of gene
transfer experiments and does not necessarily reflect the
natural time course of the human disease. Second, no animal
model completely mimics the irreversible human forms of
this disease. Monocrotaline administration not only results
in PH but also in panlung inflammation and sporadic devel-
opment of adenocarcinomas.25 Ang-1–induced PH causes
smooth muscle cell vascular hyperplasia but rarely results in
the development of plexiform lesions in the lung, which are
commonly seen in end-stage human PH.7,26 Finally, animals
with hypoxia-induced PH have reversal of clinical disease
when they are returned to normoxic conditions. Despite
these limitations, we show that delivery of a vector contain-
ing sTIE2 to the lung vasculature was successful at prevent-
ing the development of PH in 2 models of this disease in
rodents. Our results suggest that molecular targeting of the
Ang-1–TIE2 gene axis in pulmonary endothelium might be
a novel strategy for the treatment of PH based on the genetic
profile of the pulmonary vascular wall in this disease. The
full potential of therapeutic modulation of the Ang-1–TIE2
pathway will require a greater understanding of the biology
of this signaling system in both the normal and pathologic
adult lung vasculature.
We thank Paul L. Wolf, MD, of the San Diego VA Medical
Center for help with analysis of lung slides.
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Discussion
Dr Ross M. Ungerleider (Portland, Ore). I am curious whether
you could tell us what you think it is about hypoxia-induced PH
that makes it so much different than the other forms?
Dr Thistlethwaite. Hypoxic PH is a very interesting phenom-
enon in that it is a disease that is completely reversible, unlike
c and Cardiovascular Surgery ● Volume 129, Number 2 275
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TSalmost every other type of PH, which is permanent. Basically,
there are, in the field of PH research, 2 components to this disease:
one is a reactive component of vasoconstriction, and one, a later
component, is that of smooth muscle cell proliferation in the
vascular wall.
I think that the hypoxic PH model is probably more based on
vasoconstriction and less muscular thickening than some of the
other models of PH, both human and rodent, and I think, funda-
mentally, it is a different disease at a genetic level.
Dr Robert C. Robbins (Stanford, Calif). You had to give this
before, so I would say it is a great intervention to prevent the PH.
What about after PH is already developed in these models? Have
you tried giving this intervention to see whether it would regress or
276 The Journal of Thoracic and Cardiovascular Surgery ● Febrimprove? Or, for example, in the middle of your models of
progression to PH, can it at least arrest the process once it starts,
or is it going to be required to be given up front? It really is not
going to have much clinical implication if that is the case.
Dr Thistlethwaite. Those are very interesting questions. Our
experiments have been limited by the technology of AAV. As
most of you know, AAV expresses a transgene about a month
after delivery, and therefore in our first experiments or treat-
ment, we wanted to have maximal transgene expression at the
time that the disease was clinically induced. We have not done
further studies of inducing the disease and then delivering the
transgene, but obviously this is something that we will want to
look at in the future.
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